

CURRICULUM VITAE

Pernille Byrialsen Elming, MD, PhD Miltonsvej 35 DK-8270 Højbjerg +45 61301252 pernille.elming@oncology.au.dk

Education 1998-2005	University of Southern Denmark. Medical School
2005	Cand. Med./MD
2012-2021	Specialist training in Clinical Oncology
2020	PhD
Research	
2004	University of Southern Denmark, Department of Clinical Pathology, Research assistant for professor Henrik Daa Schroeder. Parttime job mainly in stem cell research.
2015 – 2020	Enrolled as PhD student Aarhus University at Experimental Clinical Oncology, Department of Oncology, Aarhus University Hospital, Denmark
18.06 2020	PhD, Aarhus University, Denmark. Thesis:"Tumour hypoxia and the potential of using exercise and hyperthermia for its elimination"

Publications

Ditte C. Andersen, Stine J. Petersson, Louise H. Jørgensen, Peter Bollen, **Pernille B. Jensen**, Børge Teisner, Henrik D. Schroeder and Charlotte H. Jensen. (2009) Characterization of DLK1+ Cells Ermerging During Skeletal Muscle Remodelling in Response to Myositis, Myopathies, and Acute Injury. Stem Cells. <u>27:</u>989-908 (**Impact factor = 7.747**)

Pernille B. Elming, Brita S. Sørensen, Arlene L. Oei, Nicolaas A. P. Franken, Johannes Crezee, Jens Overgaard and Michael R. Horsman. (2019) Hyperthermia: The optimal treatment to overcome radiation resistance. Cancers. 11(1), 60; doi:10.3390 (Impact factor = 5.326)

Simon Lønbro, Jennifer M. Wiggins, Thomas R. Wittenborn, **Pernille B. Elming**, Lori Rice, Christine Pampo, Jennifer A. Lee, Dietmar W. Siemann and Michael R. Horsman. (2019) Reliability of blood lactate as a measure of exercise intensity in different strains of mice during forced treadmill running. PLoS One 3;14(5):e0215584. (**Impact factor = 2.740**)

Pernille B. Elming, Brita S. Sørensen, Harald Spejlborg, Jens Overgaard and Michael R. Horsman. (2020) Does the combination of hyperthermia with low LET radiation induce anti-tumor effects equivalent to those seen with high LET radiation alone? Submitted to International Journal of Hyperthermia (**Impact factor =3.980**)

Michael R. Horsman, Thomas R. Wittenborn, Patricia S. Nielsen and **Pernille B. Elming.** (2020) Tumours resitant to checkpoint inhibitors can become sensitive after treatment with vascular disrupting agents. <u>Submitted to</u> International Journal of Molecular Sciences (**Impact factor = 4.556**)

Meeting presentations

2015	"KGPP94, a small-molecule cathepsin L inhibitor – has an effect on both
	tumour initiation and metasteses formation", Tumormicroenvironment
	workshop, Vancouver, August 27-29. <u>Oral presentation</u> with abstract
2015	"Vascular disrupting agents", Research Day, Dept. of Oncology, Aarhus,
	Sept. 4. Oral presentation
2017	"Combining Vascular Disrupting Agents with Checkpoint Inhibitors to
	Improve Tumour Immunogenicity", Tumor Microenvironment
	Workshop, Miami Beach, Fl, USA, Apr. 27-29. Oral presentation with
	abstract
2017	"Combination of Vascular Disrupting Agents and Checkpoint Inhibitors:
	a Method of Increasing Tumour Immunogenicity?", BiGART, Aarhus
	Denmark, June 13-16. Poster presentation
2018	Combining of Checkoint Inhibitors with hyperthermia: a Method of
	Increasing Tumour Immunogenecity", PhD day, Aarhus University,
	Denmark. January 26. Poster presentation with abstract
2018	"Combining hyperthermia and checkpoint inhibitors: a method of
	increasing tumour immunogenicity", ESTRO, Barcelona, Spain, April 13-
	16. Oral presentation with abstract
2018	"From cold to hot: Increasing tumour immunogenicity by combining
	checkpoint inhibitors with hyperthermia", ESHO, Berlin, Germany, May
	16-19. Oral presentation with abstract. Received: 2018 ESHO-ZMT
	Young Investigator Award
2018	"Hyperthermia: Perfusion matters!" Hyperthermia Symposium,
	Amsterdam, The Netherlands, November 15-16. Invited speaker

"Combining hyperthermia and/or OXi4503 with low LET radiation is equivalent to high LET radiation alone", ESTRO 2019, Milan, April 26-30. Oral presentation with abstract.